



## Curriculum Vitae

Personal information **Olga Kholmanskikh**

### Work experience

---

1. Employer: Federal Agency for Medicines and Health Products
  - Start date: 11-2012
  - End date:
  - Position: Clinical assessor
  - Activities: Clinical assessment coordination in the therapeutic area of oncology, haemato\_oncology and paediatric haemato\_oncology; evaluation of pharmacodynamics, efficacy, safety and benefit/risk ratio of medicines within the framework of centralised, decentralised, mutual recognition and national procedures: • new marketing authorisation applications • variations of authorised medicines • scientific advices (European and national) • compassionate use and medical need programmes • clinical trial applications
  - Country: Belgium
2. Employer: Catholic University of Louvain (UCL), de Duve Institute, Ludwig Institute for Cancer Research
  - Start date: 2007
  - End date: 2009
  - Position: PhD researcher in Biomedical and Pharmaceutical sciences
  - Activities: Scientific research in cancer genetics, epigenetics and immunology
  - Country: Belgium
3. Employer: Fonds National de la Recherche Scientifique, Catholic University of Louvain (UCL), de Duve Institute, Ludwig Institute for Cancer Research
  - Start date: 2003
  - End date: 2007
  - Position: PhD researcher in Biomedical and Pharmaceutical sciences
  - Activities: Scientific research in cancer genetics, epigenetics and immunology
  - Country: Belgium
4. Employer: Perm State Medical University
  - Start date: 1998
  - End date: 2000
  - Position: MD, internship
  - Activities: Internal medicine
  - Country: Russian Federation

### Education and training

---

1. Subject: Perm State Medical University
  - Start date: 09-1992
  - End date: 06-1998
  - Qualification: University Medical Degree (M.D.)
  - Organisation: Medicine
  - Country: Russian Federation
2. Subject: Perm State Medical University, regional hospitals
  - Start date: 09-1998
  - End date: 06-2000
  - Qualification: Internship in Internal Medicine
  - Organisation: Internal Medicine
  - Country: Russian Federation
3. Subject: Free University of Brussels (ULB)
  - Start date: 09-2000
  - End date: 06-2001
  - Qualification: DES in environment management (postgraduate education, first year)
  - Organisation: Environmental sciences, toxicology, microbiology
  - Country: Belgium
4. Subject: Catholic University of Louvain (UCL)
  - Start date: 10-2001
  - End date: 09-2006
  - Qualification: DES in biomedical sciences and DEA in health sciences (postgraduate diplomas)
  - Organisation: Scientific research in cancer genetics, epigenetics and immunology
  - Country: Belgium
5. Subject: Catholic University of Louvain (UCL)
  - Start date: 10-2003
  - End date: 03-2011
  - Qualification: PhD in Biomedical and Pharmaceutical sciences
  - Organisation: Scientific research in cancer genetics, epigenetics and immunology
  - Country: Belgium
6. Subject: PHARMED, Free University of Brussels (ULB)
  - Start date: 04-2012
  - End date: 01-2013
  - Qualification: Post\_graduate programme in pharmaceutical medicine/medicines development sciences
  - Organisation: Clinical development of medicines, Clinical trials, Pharmacokinetics, Biostatistics, Drug safety evaluation, Pharmacovigilance and Regulatory Affairs,

Pharmacoeconomics & Medical Information

- Country: Belgium

7. Subject: BioWin

- Start date: 06-2012
- End date: 06-2012
- Qualification: Courses on clinical development of medicines
- Organisation: GCP\_ICH principles, Developing a clinical trial protocol, Data Management
- Country: Belgium

8. Subject: Faculty of Medicine, Free University of Brussels (ULB)

- Start date: 11-2013
- End date: 11-2013
- Qualification: Hemato\_oncology courses
- Organisation: Clinical and fundamental aspects of oncology and hemato\_oncology
- Country: Belgium

## Additional information

---

### Publications

Kholmanskikh O, van Baren N, Brasseur F, Ottaviani S, Vanacker J, Arts N, van der Bruggen P, Coulie P, and De Plaen E., "Interleukins 1 $\alpha$  and 1 $\beta$  secreted by some melanoma cell lines strongly reduce expression of MITF\_M and melanocyte\_differentiation antigens". *Int J Cancer*. 2010 Oct 1 ; 127(7), 1625\_1636.

Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C., "Expression of BORIS in melanoma: lack of association with MAGE\_A1 activation". *Int J Cancer*. 2008 Feb15; 122(4): 777\_84.

Laduron S, Deplus R, Zhou S, Kholmanskikh O, Godelaine D, De Smet C, Hayward SD, Fuks F, Boon T, De Plaen E. "MAGE\_A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription". *Nucleic Acids Res*. 2004 Aug17; 32(14): 4340\_50.

M. Van den Bulcke, S. Boccia, A. De Censi, L. Decoster, A. Federici, F. Nowak, O. Kholmanskikh, M. Peeters, C. Rolfo, R. Salgado, R. Schmützler and J. Vermeesch "Policy Paper on Public Health Genomics in Cancer" In : "Cancer Control Joint Action Policy Papers"

Vermaelen K, Waeytens A, Kholmanskikh O, Van den Bulcke M, Van Valckenborgh E. "Perspectives on the integration of Immuno\_Oncology Biomarkers and drugs in a Health Care setting." *Semin Cancer Biol*. 2017 Nov 21.

A. Hébrant PhD, M. Lammens MD, PhD, C. Van den Broecke MD, N. D'Haene MD, PhD, J. Van den Oord MD, PhD, A. Vanderstichele MD, PhD, A. Dendooven MD, PhD, P. Neven MD, PhD, K. Punie MD, G. Floris MD, PhD, J. Van der Meulen PhD, HA. Poirel MD, PhD, C. Dooms MD, PhD, S. Rottey MD, PhD, T. Boterberg MD, PhD, L. Brochez MD, PhD, M.C. Burlacu MD, G. Costante MD, D. Creytens MD, PhD, P. De Paepe MD, PhD, R. De Pauwn MD, B. Decallonne MD, PhD, F. Dedeurwaerdere MD, H. Denys MD, PhD, L. Ferdinande MD, PhD, R. Forsyth MD, PhD, M. Garmyn MD, PhD, T. Gevaert MD, PhD, J. De Grève MD, PhD, E. Govaerts MD, E. Hauben MD, PhD, J. Kerger MD, PhD, O. Kholmanskikh Van Criekingen MD, PhD, V. Kruse MD, PhD, Y. Lalami MD, L. Lapeire MD, PhD, P. Lefesvre MD, PhD, J.P. Machiels MD, PhD, B. Maes MD, PhD, G. Martens MD, PhD, M. Rimmelink MD, PhD, I. Salmon MD, PhD, R. Sciot MD, PhD, S. Tejpar MD, PhD, K. Van de Vijver MD, PhD, L. Van de Voorde MD, I. Van den Berghe MD, A. Van den Bruel MD, K. Vandecasteele MD, PhD, L. Vanwallegem MD, K. Vermaelen MD, PhD, R. Salgado MD, PhD, E. Wauters MD, PhD, B. Weynand MD, PhD, E. Van Valckenborgh PhD, G. Raicevic PhD, M. Van den Bulcke PhD, P. Pauwels MD, PhD. "Algorithms for molecular testing in solid tumours." *Belgian Journal of Medical Oncology*, 2019;13(7):286-95

Papadoulou I, Mueller\_Berghaus J, Beuneu C, Ali S, Hofner B, Petavy F, Tzozani K, Miermont A, Norga K, Kholmanskikh O, Leest T, Schuessler\_Lenz M, Salmonson T, Gisselbrecht C, Garcia JL, Pignatti F. "EMA Review of Axicabtagene Ciloleucelel (Yescarta) for the Treatment of Diffuse Large B\_Cell Lymphoma ". *Oncologist*, 2020 Apr 27.

Karres D, Lesa G, Ligas F, Annunen P, van Dartel M, Demolis P, Galluzzo S, Herold R, Kholmanskikh van Criekingen O, Stoyanova\_Beninska V, Norga K. "Can a multi\_stakeholder prioritisation structure support regulatory decision making? A review of paediatric oncology strategy forums reflecting on challenges and opportunities of this concept", *Clin Pharmacol Ther*. 2020 Sep;108(3):553\_556.

Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo\_Branco I, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel\_Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap T, Ratain M, Seymour L. "Oncology phase I trial design and conduct: time for a change \_ MDICT Guidelines 2022." *Annals of Oncology*. Volume 34, Issue 1, January 2023: 48\_60

Yap C, Solovyeva O, de Bono J, Rekowski J, /.../ Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. "Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance" *BMJ*. 2023 Oct 20;383:e076387.

Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, /.../ Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. "Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance." *BMJ*. 2023 Oct 20;383:e076386.

### Projects

Academic research projects during PhD thesis (tumour biology and immunology)

Personalised medicine, genomics and NGS projects (Belgian Cancer Centre)

Belgian Mirror group Europe's Beating Cancer Plan

### Memberships

Oncology Working Party - observer since 2014, member since 2019

Alternate member of the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA) since 2023, joint CAT-SAWP member since 2024

Member of the Methodology Working Party since 2024

Methodology and Innovation subgroup member at CTCG (HMA)

SIOP member

### Other Relevant Information